Alzheimers Disease Drug Development Program (U01)
The summary for the Alzheimers Disease Drug Development Program (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Alzheimers Disease Drug Development Program (U01): Purpose. The objective of this solicitation is to stimulate research in the pre-clinical development and testing of novel therapeutic compounds aimed at slowing, halting, or reversing the progressive decline in cognitive function and modifying the behavioral symptoms in Alzheimer's disease (AD); or delaying the onset of or preventing AD, mild cognitive impairment (MCI), or age-related cognitive decline. This initiative is intended to stimulate activities focused on providing sufficient data to submit an Investigational New Drug (IND) application to the Food and Drug Administration to begin human clinical testing of potential new therapies. For this program neither mechanistic/basic studies nor clinical trials will be supported; only applications to develop a therapy will be accepted. Mechanism of Support. This FOA will utilize the U01 grant mechanism. Funds Available and Anticipated Number of Awards. NIA has set aside $3.0 M in total costs in FY2011 for applications submitted in response to this program announcement. However, because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received
Federal Grant Title: | Alzheimers Disease Drug Development Program (U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-10-205 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.866 |
CFDA Descriptions: | Aging Research |
Current Application Deadline: | May 07, 2013 |
Original Application Deadline: | May 07, 2013 |
Posted Date: | May 21, 2010 |
Creation Date: | May 21, 2010 |
Archive Date: | Jun 07, 2013 |
Total Program Funding: | $3,000,000 |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed)
- • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...
- • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...
- • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...
- • Research Training in Aging for Medical Students (T35)
- • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...
- • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...
- • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
- More Grants from the National Institutes of Health
- • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)